RIBOLIFE-B Shares Surge Over 7% in Morning Session Following Successful Phase IIb Submission for Vortosiran in Stroke Prevention

Stock News04-15

RIBOLIFE-B (06938) rose more than 7% during early trading. At the time of writing, the stock was up 6.04%, trading at HK$72.9, with a turnover of HK$11.7261 million. The company announced that its core product, Vortosiran (RBD4059), has successfully submitted a Phase IIb clinical trial application (CTA) to the European Medicines Agency (EMA) for stroke prevention in atrial fibrillation (SPAF) patients. This marks the world’s first small interfering RNA (siRNA) Factor XI (FXI) inhibitor to enter clinical trials for atrial fibrillation (AF), representing a significant milestone in the clinical development of siRNA therapies in the anticoagulation field. RIBOLIFE-B has planned a series of Phase IIb clinical studies covering multiple thrombotic and cardiovascular indications, with the recently submitted trial, coded ORBIT-XI-AF, being one of them. Following the completion of Vortosiran’s Phase IIa trial for coronary artery disease (CAD), this submission further strengthens the product’s position as the fastest-developing FXI-targeting small nucleic acid drug globally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182190562?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-15 11:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182190562","market":"us","top_or_hot":-1,"title":"RIBOLIFE-B Shares Surge Over 7% in Morning Session Following Successful Phase IIb Submission for Vortosiran in Stroke Prevention","media":"Stock News","content":"<p>RIBOLIFE-B (06938) rose more than 7% during early trading. At the time of writing, the stock was up 6.04%, trading at HK$72.9, with a turnover of HK$11.7261 million. The company announced that its core product, Vortosiran (RBD4059), has successfully submitted a Phase IIb clinical trial application (CTA) to the European Medicines Agency (EMA) for stroke prevention in atrial fibrillation (SPAF) patients. This marks the world’s first small interfering RNA (siRNA) Factor XI (FXI) inhibitor to enter clinical trials for atrial fibrillation (AF), representing a significant milestone in the clinical development of siRNA therapies in the anticoagulation field. RIBOLIFE-B has planned a series of Phase IIb clinical studies covering multiple thrombotic and cardiovascular indications, with the recently submitted trial, coded ORBIT-XI-AF, being one of them. Following the completion of Vortosiran’s Phase IIa trial for coronary artery disease (CAD), this submission further strengthens the product’s position as the fastest-developing FXI-targeting small nucleic acid drug globally.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RIBOLIFE-B Shares Surge Over 7% in Morning Session Following Successful Phase IIb Submission for Vortosiran in Stroke Prevention</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRIBOLIFE-B Shares Surge Over 7% in Morning Session Following Successful Phase IIb Submission for Vortosiran in Stroke Prevention\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-15 11:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>RIBOLIFE-B (06938) rose more than 7% during early trading. At the time of writing, the stock was up 6.04%, trading at HK$72.9, with a turnover of HK$11.7261 million. The company announced that its core product, Vortosiran (RBD4059), has successfully submitted a Phase IIb clinical trial application (CTA) to the European Medicines Agency (EMA) for stroke prevention in atrial fibrillation (SPAF) patients. This marks the world’s first small interfering RNA (siRNA) Factor XI (FXI) inhibitor to enter clinical trials for atrial fibrillation (AF), representing a significant milestone in the clinical development of siRNA therapies in the anticoagulation field. RIBOLIFE-B has planned a series of Phase IIb clinical studies covering multiple thrombotic and cardiovascular indications, with the recently submitted trial, coded ORBIT-XI-AF, being one of them. Following the completion of Vortosiran’s Phase IIa trial for coronary artery disease (CAD), this submission further strengthens the product’s position as the fastest-developing FXI-targeting small nucleic acid drug globally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06938","symbol_name":"瑞博生物-B","start_time":0,"source_url":"","article_id":"1182190562","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182190562","pubTimestamp":1776224004,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"RIBOLIFE-B (06938) rose more than 7% during early trading. At the time of writing, the stock was up 6.04%, trading at HK$72.9, with a turnover of HK$11.7261 million. The company announced that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06938":"瑞博生物-B","VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技"},"translate_title":"在成功提交Vortosiran用于中风预防的IIb期研究后，RIBOLIFE-B股价早盘飙升超过7%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":1,"VXUS":1},"content_text":"RIBOLIFE-B (06938) rose more than 7% during early trading. At the time of writing, the stock was up 6.04%, trading at HK$72.9, with a turnover of HK$11.7261 million. The company announced that its core product, Vortosiran (RBD4059), has successfully submitted a Phase IIb clinical trial application (CTA) to the European Medicines Agency (EMA) for stroke prevention in atrial fibrillation (SPAF) patients. This marks the world’s first small interfering RNA (siRNA) Factor XI (FXI) inhibitor to enter clinical trials for atrial fibrillation (AF), representing a significant milestone in the clinical development of siRNA therapies in the anticoagulation field. RIBOLIFE-B has planned a series of Phase IIb clinical studies covering multiple thrombotic and cardiovascular indications, with the recently submitted trial, coded ORBIT-XI-AF, being one of them. Following the completion of Vortosiran’s Phase IIa trial for coronary artery disease (CAD), this submission further strengthens the product’s position as the fastest-developing FXI-targeting small nucleic acid drug globally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182190562","isCrawlerRequest":true}